{"id":61234,"date":"2026-03-25T13:57:24","date_gmt":"2026-03-25T05:57:24","guid":{"rendered":"https:\/\/flcube.com\/?p=61234"},"modified":"2026-03-25T13:57:25","modified_gmt":"2026-03-25T05:57:25","slug":"qilu-pharmas-qls31905-wins-fda-orphan-drug-designation-first-in-class-claudin18-2-cd3-bispecific-enters-phase-iii-for-pancreatic-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61234","title":{"rendered":"Qilu Pharma’s QLS31905 Wins FDA Orphan Drug Designation \u2013 First\u2011in\u2011Class Claudin18.2\/CD3 Bispecific Enters Phase III for Pancreatic Cancer"},"content":{"rendered":"\n

Qilu Pharmaceutical Co., Ltd.<\/strong> announced that QLS31905<\/strong>, its Claudin18.2\/CD3 bispecific T\u2011cell engager (BsAb)<\/strong>, has received Orphan Drug Designation (ODD)<\/strong> from the US Food and Drug Administration (FDA)<\/strong> for pancreatic cancer<\/strong> \u2013 validating the first\u2011in\u2011class<\/strong> candidate that has already advanced to Phase III clinical development in China<\/strong> as a first\u2011line combination therapy<\/strong> for this lethal malignancy.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>US Food and Drug Administration (FDA)<\/td><\/tr>
Designation<\/strong><\/td>Orphan Drug Designation (ODD)<\/strong><\/td><\/tr>
Product<\/strong><\/td>QLS31905 \u2013 Claudin18.2\/CD3 bispecific antibody (BsAb)<\/td><\/tr>
Company<\/strong><\/td>Qilu Pharmaceutical Co., Ltd.<\/td><\/tr>
Target Indication<\/strong><\/td>Pancreatic cancer<\/strong><\/td><\/tr>
Global First<\/strong><\/td>World’s first<\/strong> Claudin18.2\/CD3 bispecific to enter Phase III<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mechanism of Action \u2013 Bispecific T\u2011Cell Engager<\/h2>\n\n\n\n
Component<\/th>Target<\/th>Functional Outcome<\/th><\/tr><\/thead>
Arm 1<\/strong><\/td>Claudin18.2<\/strong> on tumor cells<\/td>Tumor\u2011specific antigen recognition<\/td><\/tr>
Arm 2<\/strong><\/td>CD3<\/strong> on T cells<\/td>T\u2011cell recruitment and activation<\/td><\/tr>
Mechanism<\/strong><\/td>Physical bridging of tumor and T cells<\/td>Sustained tumor cell killing<\/strong> via redirected cytotoxicity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Development Status<\/h2>\n\n\n\n
Study<\/th>Design<\/th>Status<\/th>Strategic Significance<\/th><\/tr><\/thead>
Phase III (China)<\/strong><\/td>QLS31905 + chemotherapy vs. standard of care<\/td>Ongoing<\/strong><\/td>First\u2011line advanced pancreatic cancer<\/strong> \u2013 highest unmet need setting<\/td><\/tr>
Patient Population<\/strong><\/td>Advanced pancreatic cancer<\/td>Enrollment in progress<\/td>Aggressive disease with limited effective options<\/td><\/tr>
Global Expansion<\/strong><\/td>US\/EU Phase III planned<\/td>ODD enables accelerated pathway<\/td>FDA priority review voucher eligibility upon approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Orphan Drug Designation Benefits<\/h2>\n\n\n\n
Benefit<\/th>Strategic Value<\/th><\/tr><\/thead>
7\u2011year market exclusivity<\/strong> (US)<\/td>Competitive protection post\u2011approval<\/td><\/tr>
Tax credits<\/strong> for clinical development<\/td>Reduced R&D cost burden<\/td><\/tr>
Waiver of FDA application fees<\/strong><\/td>Lower regulatory submission costs<\/td><\/tr>
Potential priority review voucher<\/strong><\/td>Accelerated approval timeline; transferable asset value<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Positioning<\/h2>\n\n\n\n
Dimension<\/th>Pancreatic Cancer Landscape<\/th>QLS31905 Position<\/th><\/tr><\/thead>
Disease Burden<\/strong><\/td>3rd leading cause of cancer death<\/strong>; 5\u2011year survival <10%; ~60,000 new US cases annually<\/td>High unmet need; orphan status justified by low prevalence<\/td><\/tr>
Standard of Care<\/strong><\/td>FOLFIRINOX or gemcitabine\/nab\u2011paclitaxel (first\u2011line); limited efficacy<\/td>First\u2011line bispecific addition<\/strong> \u2013 potential paradigm shift<\/td><\/tr>
Claudin18.2 Prevalence<\/strong><\/td>~50\u201170% of pancreatic cancers express Claudin18.2<\/td>Biomarker\u2011driven patient selection; companion diagnostic opportunity<\/td><\/tr>
Competitive Pipeline<\/strong><\/td>Zolbetuximab (Claudin18.2 mAb, Astellas\/Bristol\u2011Myers Squibb) \u2013 Phase III; CAR\u2011Ts in early development<\/td>Bispecific T\u2011cell engager<\/strong> mechanism differentiated from mAb; potential for superior T\u2011cell activation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Outlook<\/h2>\n\n\n\n